Posted by Michael Wonder on 24 Apr 2023
Lantheus and POINT Biopharma announce FDA grants fast track designation for ¹⁷⁷Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer
24 April 2023 - Lantheus Holdings today announced the US FDA has granted fast track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer.
PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added 177Lu.
